• [email protected]
  • +971 507 888 742
Submit Manuscript
SciAlert
  • Home
  • Journals
  • Information
    • For Authors
    • For Referees
    • For Librarian
    • For Societies
  • Contact
  1. Pakistan Journal of Biological Sciences
  2. Vol 18 (6), 2015
  3. 300-303
  • Online First
  • Current Issue
  • Previous Issues
  • More Information
    Aims and Scope Editorial Board Guide to Authors Article Processing Charges
    Submit a Manuscript

Pakistan Journal of Biological Sciences

Year: 2015 | Volume: 18 | Issue: 6 | Page No.: 300-303
DOI: 10.3923/pjbs.2015.300.303

Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend



Total views 561

Search


Authors


Rasekhjahromi Athar

Country: Iran

Maalhagh Mehrnoosh

Country: Iran

Hosseinpoor Masoumeh

Country: Iran

Farhang Hooshmand

Country: Iran

Alavi Fatemeh

Country: Iran

Keywords


  • clomiphene citrate
  • Letrozole
  • PCOS
  • tamoxifen
Research Article

A Clomiphene Citrate and Letrozol Varsus Tamoxifen and Letrozole as an Infertility Treatment in Women with Polycystic Ovary Syndrome

Rasekhjahromi Athar, Maalhagh Mehrnoosh, Hosseinpoor Masoumeh, Farhang Hooshmand and Alavi Fatemeh
The polycystic ovary syndrome (PCOs) affects 5-10% of reproductive age women and it is the most common cause of unovulatory infertility. The aim of this clinical trial was to compare the combination therapy of letrozole and clomiphene with letrozole and tamoxifen as an infertility treatment in women with the polycystic ovary syndrome. In this study 9 infertile women between 18-40 years with the polycystic ovary syndrome who had no major medical disorders enrolled in this clinical trial. Patients were randomized in to 2 groups: one group was treated with Clomiphene Citrate (CC) 50 mg twice daily and letrozole 2.5 mg twice daily for 5 days (from day 3-7 of menstrual cycle) and group 2 took tamoxifen 10 mg twice daily and letrozole 2.5 mg twice daily for 5 days (from day 3-7 of menstrual cycle). Trans vaginal ultrasonography (TVS) was performed at the day 7 in order to determine number of follicles, size of follicles and Endometrial Thickness (ET). Pregnancy rate in the group of women who received tamoxifen and letrozole (Group B) was more than women who received CC and letrozole (Group A) (2.2% in group A vs. 17.8% in group B) that there is significant difference between two groups (p = 0.01). There is no significant association between two groups in incidence of OHSS, endometrial thickness and follicular size. It suggested co-administration of letrozole and tamoxifen was more effective due to low cost, low complication and greater access as an infertility treatment.
PDF Fulltext XML References Citation

How to cite this article

Rasekhjahromi Athar, Maalhagh Mehrnoosh, Hosseinpoor Masoumeh, Farhang Hooshmand and Alavi Fatemeh, 2015. A Clomiphene Citrate and Letrozol Varsus Tamoxifen and Letrozole as an Infertility Treatment in Women with Polycystic Ovary Syndrome. Pakistan Journal of Biological Sciences, 18: 300-303.

DOI: 10.3923/pjbs.2015.300.303

URL: https://scialert.net/abstract/?doi=pjbs.2015.300.303

Related Articles

Assessing an Optimal Regimen in Treatment of Infertility (Clomiphene Citrate, Tamoxifen and Vit. E Versus Estrogen, Letrozole and Tamoxifen): A Double blind Control Trial

Leave a Comment


Your email address will not be published. Required fields are marked *

Useful Links

  • Journals
  • For Authors
  • For Referees
  • For Librarian
  • For Socities

Contact Us

Office Number 1128,
Tamani Arts Building,
Business Bay,
Deira, Dubai, UAE

Phone: +971 507 888 742
Email: [email protected]

About Science Alert

Science Alert is a technology platform and service provider for scholarly publishers, helping them to publish and distribute their content online. We provide a range of services, including hosting, design, and digital marketing, as well as analytics and other tools to help publishers understand their audience and optimize their content. Science Alert works with a wide variety of publishers, including academic societies, universities, and commercial publishers.

Follow Us
© Copyright Science Alert. All Rights Reserved